Skip to content
Summer 2026 · 26% off every plan with SUMMER26 See pricing
Optionomics
CON · 10-Q filed May 7, 2026

CON earnings analysis

What we found in CON's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.

Our reading of the filing · Free to read, no account needed

Concentra Group Holdings Parent, Inc. reported a strong Q1 2026 with revenue of $569.6 million, exceeding estimates by 2.87%, and EPS of $0.40, surpassing expectations by 17.65%. This represents a 13.7% growth in revenue year-over-year, driven by increased patient visits and efficient operations.

What stood out

The parts that mattered.

Pulled out of the filing itself, with the figures the company reported.

Revenue Growth
Revenue increased 13.7% from $500.8M in Q1 2025 to $569.6M in Q1 2026.
EPS Surprise
Reported EPS of $0.40 beat estimates of $0.34 by 17.65%.
Improved Margins
Gross margin improved to 29.9% from 28.7%, demonstrating better cost management.
Higher Adjusted EBITDA
Adjusted EBITDA rose to $120.7M, up from $102.7M, marking a 17.5% increase.
Increased Patient Visits
Total patient visits increased by 6.7%, reaching 3,419,091 in Q1 2026.
Share Repurchase Program
Repurchased $15M worth of shares during the quarter, with $65M remaining for future buybacks.
What to watch

And the other side of it.

The offsets in the same document — the things a summary that only listed the good news would have left out.

High Debt Levels
Total debt remains high at $940.5M with significant interest expense of $26M.
Regulatory Scrutiny
The company faces risks from increased regulatory scrutiny impacting operations.
Litigation Risks
Ongoing litigation may expose the company to substantial liabilities, affecting future cash flows.
The numbers

What they reported.

What the company itself reported, taken out of the document.

What survived to operating profit
Of every $100 of revenue Cost of sales $70 Operating expenses $13 Left as operating profit $17
Percentages of revenue, taken from the filing. Drawn this way because it holds whatever scale the company reports in.
Earnings per share
$0.4
Gross margin
29.9%
Operating margin
16.8%
Segment
Occupational health centers: 91%
Segment
Onsite health clinics: 7%
Segment
Other businesses: 2%
Guidance

What they said about what is next.

Management raised full-year revenue guidance to $2.275B-$2.375B and adjusted EBITDA to $460M-$480M.

How we read the filing overall

The filing reads better than the one before it.

One reading of one document. It is not advice, and it is not a forecast.
Earlier filings

What came before.

10-K · February 26, 2026
Concentra (CON) presents a strategy focused on scale in occupational health, expanding onsite clinic capability and telemedicine while pursuing M&A to grow reach. 2025 revenue was $2,163.4 million, driven primarily by…
10-Q · November 6, 2025
Concentra reported Q3 revenue of $572,800 (in thousands) and GAAP diluted EPS of $0.38 for the three months ended September 30, 2025. Revenue rose year-over-year from $489,638 (in thousands) while gross margin remained…

This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.

Read the next one first.

We read every filing CON makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.

Cancel anytime · Month to month · Switch tiers whenever